As the executive leadership of The Geneva Foundation, we are proud of our organizational accomplishments and efforts in 2016. Geneva’s purpose is impressive and expansive – our mission to advance military medicine is supported around the world through the dedication of over 525 researchers, research personnel, and administrative professionals. Our highly-skilled and diverse team is guided by an unwavering dedication to exceptional science, lasting relationships, distinguished collaborators, and sound business operations.

**GENEVA SETS ITSELF APART BY OFFERING A HIGH LEVEL OF SERVICE AND EXPERTISE THROUGH OUR COMMITMENT TO SHARED VALUES OF INTEGRITY, SUPERIOR CUSTOMER SERVICE, QUALITY, TEAMWORK, INNOVATION, AND RESPECT FOR ALL.**

While each of these core values are essential, we have learned that teamwork is vital to Geneva’s sustainability and growth. As Geneva’s Executive Team, our initiatives are informed through collaborations with our Board of Directors and Scientific Advisory Board, as well as with world-renowned researchers; dedicated sponsors; government, academic, and industry partners; and highly-skilled research professionals. In each of our capacities, we work toward the common goal of advancing Geneva’s mission around the world. Teamwork enables our organization to evolve, exposes us to enlightened ideas, and challenges us to think, grow, and act in ways that enhance Geneva’s impact.

Teamwork was one of the primary forces behind Geneva’s growth in 2016. Broadly speaking, our efforts as an organization were focused on the acquisition of new research opportunities and the cultivation of mission-critical partnerships. While some of these efforts have resulted in distinct programmatic gains, others have served an equally important purpose – setting the stage for expansion into new areas of opportunity to address unmet needs.

The Executive Team remains humbled by the commitment of so many remarkable people working in concert for Geneva’s success – you have our gratitude and our pledge to continue to work tirelessly in support of you and our mission.

**Elise W. Huszar, MBA**  
President

**Jane S. Taylor, BSN**  
Founder & Chief Strategy Officer

**David E. Blanford, CPA**  
Chief Financial Officer

---

**EXECUTIVE MESSAGE**

---

**FOUNDED IN 1993, THE GENEVA FOUNDATION IS A 501(C)3 NON-PROFIT ORGANIZATION WHOSE MISSION IS TO SUPPORT AND ADVANCE INNOVATIVE MEDICAL RESEARCH WITHIN THE U.S. MILITARY. GENEVA BUILDS ENDURING PARTNERSHIPS DEDICATED TO THE HEALTH AND WELL-BEING OF U.S. SERVICE MEMBERS, THEIR FAMILIES, AND THE GLOBAL COMMUNITY.**

---

**BOARD OF DIRECTORS**

Geneva acknowledges the dedication and contributions of the Board of Directors, whose guidance has been, and continues to be, fundamental to the success of the organization:

**MICHAEL W. HANSSH**  
Chair  
13 Years of Service

**ELISE W. HUSZAR, MBA**  
Secretary  
21 Years of Service

**DAVID BLANFORD, CPA**  
Treasurer  
5 Years of Service

**JANE S. TAYLOR, BSN**  
Founder  
23 Years of Service

**DAVID SHOUltZ, PhD, MBA**  
Scientific Advisory Board Chair  
7 Years of Service

**C.W. HERCHOLD, MBA**  
3 Years of Service

**DAVID A. LITTLE, JD**  
5 Years of Service

**LINDA NGUYEN**  
5 Years of Service

**SCOTT O’HALLORAN, JD**  
7 Years of Service

**CLIFF ROBERTSON, MD, MBA**  
10 Years of Service

**MAJOR GENERAL (Ret.) FRANK SCOGGINS**  
6 Years of Service

**COLONEL (Ret.) PATRICK STEEL**  
7 Years of Service
As the Chief of Viral Immunology within the Virology Division at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID), Dr. John M. Dye, Jr. oversees the execution of research programs in medical countermeasures against viral biological warfare agents in a high-hazard, multi-suite, bio-containment laboratory that operates at Biosafety Levels 2, 3, and 4. Dr. Dye's research focuses on filovirus vaccines and therapeutics, with the ultimate aim to counteract the Ebola virus and other high risk pathogens.

“It is no question that Dr. Dye’s work is innovative – he has been on the forefront of research and the development of filovirus vaccines and therapeutics throughout his career and during his partnership with Geneva,” said Geneva’s President Elise Huszar. “Dr. Dye’s ability to continue rapid innovation in response to the recent Ebola virus epidemic is impressive, as is his commitment to research collaboration and integrity.”

Dr. Dye is on the cutting edge of research and development of medical countermeasures against filoviruses (e.g., Ebola virus, Sudan virus, and Marburg virus) and other biological threat agents. Since 2012, Dr. Dye has been traveling to Uganda to track the immune response in over 200 survivors of Ebola virus disease. Specifically, he assesses the immune responses of these survivors over time in hopes of determining an “immune profile” to drive vaccine and therapeutic development for the future. His extensive network of research collaborators has influenced basic science research on various aspects of virology and immunology, including the identification and publication of filovirus and Lassa virus receptors in the journals Nature and Science, respectively. These findings have driven protein-specific medical countermeasures against both viruses to provide a treatment option.

Since 2013, Geneva has proudly supported six research projects in partnership with Dr. Dye. His current funded NIH ROI research award, the objective of which is to develop an antibody-based immunotherapy for the treatment and management of Sudan virus infection, directly addresses a gap in the current Ebola virus therapeutics portfolio. If successful, it will provide an effective countermeasure against Sudan virus that is positioned for investigational new drug (IND)-enabling studies.

Geneva’s Scientific Advisory Board provides scientific consult, advisement, and direction to Geneva’s senior leadership, program directors, principal investigators, and research administrators. The Scientific Advisory Board serves as a strategic partner to ensure the science behind the research remains relevant, sustainable, and innovative.

**DR. DYE’S ABILITY TO CONTINUE RAPID INNOVATION IN RESPONSE TO THE RECENT EBOLA VIRUS EPIDEMIC IS IMPRESSIVE.**

**ELISE HUSZAR, PRESIDENT THE GENEVA FOUNDATION**
Geneva proudly supports medical research at over 55 federal laboratories and military treatment facilities worldwide.

### Principal Investigators Worldwide

**Alabama**
- U.S. Army Aeromedical Research Laboratory

**Arizona**
- Branch Medical Clinic, Marine Corps Air Station

**California**
- David Grant USAF Medical Center
- Naval Hospital Camp Pendleton
- Naval Hospital Twentynine Palms
- Naval Medical Center San Diego
- Palo Alto Institute of Research & Education
- San Francisco VA Medical Center

**Colorado**
- Evans Army Community Hospital
- U.S. Air Force Academy Hospital

**Connecticut**
- Naval Submarine Medical Research Laboratory

**Florida**
- Navy Experimental Diving Unit

**Georgia**
- Dwight D. Eisenhower Army Medical Center
- Martin Army Community Hospital
- Telemedicine & Advanced Technology Research Center’s Mobile Health Innovation Center
- Winn Army Medical Center

**Hawaii**
- Tripler Army Medical Center

**Kentucky**
- Blanchfield Army Community Hospital

**Maryland**
- Andrew Air Force Base
- Malcolm Grow (GROW) Medical Clinic
- National Cancer Institute
- National Center for Advancing Translational Sciences
- National Institutes of Deafness & Other Communication Disorders
- Naval Medical Research Center
- Naval Medical Research Center - Frederick
- Telemedicine & Advanced Technology Research Center
- U.S. Army Center for Environmental Health Research
- U.S. Army Medical Research Institute of Infectious Diseases
- U.S. Army Medical Research Institute of Chemical Defense
- Walter Reed Army Institute of Research
- Walter Reed National Military Medical Center

**North Carolina**
- Whidbey Island Naval Hospital
- Womack Army Medical Center

**Ohio**
- Wright-Patterson Medical Center

**Oregon**
- Portland VA Medical Center

**South Carolina**
- Moncrief Army Health Clinic

**Texas**
- AMEDD Center & School
- Brooke Army Medical Center
- Brooks City-Base (Brooks Clinic)
- Carl R. Darnell Army Medical Center
- U.S. Army Institute of Surgical Research
- William Beaumont Army Medical Center

**Virginia**
- Fort Belvoir Community Hospital
- Naval Medical Center Portsmouth

**Washington**
- Geneva Corporate Headquarters
- Madigan Army Medical Center
- National Center for Telehealth & Technology

**Washington D.C.**
- Bolling Air Force Base
- National Center for PTSD

### Supporting Research Programs
- Over 525 employees worldwide
- 216 organizations
- 175 employees hired in 2016
- 530 research programs
- 160 sponsors and collaborating partners
- $309,021,149 in submissions for the year
- Geneva’s grants & contracts departments submitted 160 proposals, totaling $54,605,521
Geneva is awarded six TriService Nursing Research Program awards, to be conducted at Andrews Air Force Base, Landstuhl Regional Army Medical Center, Womack Army Medical Center, Wright-Patterson Air Force Base, and U. S. Army Graduate Program in Anesthesia Nursing.

Geneva enters into a Memorandum of Understanding with the Uniformed Services University of the Health Sciences to collaborate on multiple activities for the purpose of conducting medical research and education within the DoD and nationwide.

In honor of Research Month, Geneva employees attend symposiums and events nationwide at military treatment facilities including Dwight D. Eisenhower Army Medical Center, Madigan Army Medical Center, San Antonio Military Medical Center, Walter Reed National Military Medical Center, and Womack Army Medical Center.

Pre-clinical testing for Geneva Investigator Dr. Amy Shurtleff’s newly-developed Hantavirus DNA vaccine commences in Chicago, IL.

Geneva’s Community Giving Program supports joint Base Lewis-McChord’s Veterans Appreciation Day & Health Fair, Nellis Air Force Base’s Clinical Investigation Research Symposium, and the Alan Magill Malaria Symposium at Walter Reed Army Institute of Research.

In honor of Research Month, Geneva hosts the 11th annual National Liver Conference in Dallas, Texas.

Geneva participates in the Ride to Recovery Honor Ride in the National Capital Region, raising funds for Project HERO and also participates in Race for a Soldier at Gig Harbor, WA raising money for the Permission to Start Dreaming (PTSD) Foundation.

Geneva receives a cooperative agreement from Naval Research Laboratory for the initial Phase I funding for the formation of the 4D Bioprinting, Biofabrication, and Biomanufacturing Consortium (4D Bio3).

Geneva partners with the Jonas Center for Nursing and Veterans Healthcare to support Geneva’s first scholarship for a doctoral nursing candidate. The scholarship, matched by Johns Hopkins University, funds Johns Hopkins School of Nursing doctoral candidate Tamar U. Rodney, MSN, RN, PMHNP-BC, whose research goals focus around molecular biomarkers of post-traumatic stress disorder in veterans with traumatic brain injury.

Geneva’s Scientific Advisory Board welcomes two new members, Eleanor F. Bond, PhD, RN, FAAN and Brigadier General (Ret.) John J. Donnelly, PhD.

Founder and Chief Strategy Officer, Jane Taylor, presents at the Tacoma-Pierce County Chamber Spotlight! on Business Awards.

Geneva’s Scientific Advisory Board hosts its annual meeting with visits to the Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center.


Geneva’s President, Elise Huszar, celebrates 20 years of Geneva leadership, beginning in 1996 as the first full-time Executive Director, and serving as President since 1998.

Geneva Investigator Dr. Travis Warren, in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Gilead Sciences, receives an award to conduct preclinical development of GS-5734 for the treatment of Ebola Virus and other filovirus infections.

Geneva is awarded six TriService Nursing Research Program awards, to be conducted at Andrews Air Force Base, Landstuhl Regional Army Medical Center, Womack Army Medical Center, Wright-Patterson Air Force Base, and U. S. Army Graduate Program in Anesthesia Nursing.

Geneva is awarded six TriService Nursing Research Program awards, to be conducted at Andrews Air Force Base, Landstuhl Regional Army Medical Center, Womack Army Medical Center, Wright-Patterson Air Force Base, and U. S. Army Graduate Program in Anesthesia Nursing.

Geneva enters into a Memorandum of Understanding with the Uniformed Services University of the Health Sciences to collaborate on multiple activities for the purpose of conducting medical research and education within the DoD and nationwide.

In honor of Research Month, Geneva employees attend symposiums and events nationwide at military treatment facilities including Dwight D. Eisenhower Army Medical Center, Madigan Army Medical Center, San Antonio Military Medical Center, Walter Reed National Military Medical Center, and Womack Army Medical Center.

Pre-clinical testing for Geneva Investigator Dr. Amy Shurtleff’s newly-developed Hantavirus DNA vaccine commences in Chicago, IL.

Geneva’s Community Giving Program supports joint Base Lewis-McChord’s Veterans Appreciation Day & Health Fair, Nellis Air Force Base’s Clinical Investigation Research Symposium, and the Alan Magill Malaria Symposium at Walter Reed Army Institute of Research.

In honor of Research Month, Geneva hosts the 11th annual National Liver Conference in Dallas, Texas.

Geneva participates in the Ride to Recovery Honor Ride in the National Capital Region, raising funds for Project HERO and also participates in Race for a Soldier at Gig Harbor, WA raising money for the Permission to Start Dreaming (PTSD) Foundation.

Geneva receives a cooperative agreement from Naval Research Laboratory for the initial Phase I funding for the formation of the 4D Bioprinting, Biofabrication, and Biomanufacturing Consortium (4D Bio3).

Geneva partners with the Jonas Center for Nursing and Veterans Healthcare to support Geneva’s first scholarship for a doctoral nursing candidate. The scholarship, matched by Johns Hopkins University, funds Johns Hopkins School of Nursing doctoral candidate Tamar U. Rodney, MSN, RN, PMHNP-BC, whose research goals focus around molecular biomarkers of post-traumatic stress disorder in veterans with traumatic brain injury.

Geneva’s Scientific Advisory Board welcomes two new members, Eleanor F. Bond, PhD, RN, FAAN and Brigadier General (Ret.) John J. Donnelly, PhD.

Founder and Chief Strategy Officer, Jane Taylor, presents at the Tacoma-Pierce County Chamber Spotlight! on Business Awards.

Geneva’s Scientific Advisory Board hosts its annual meeting with visits to the Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center.


Geneva’s President, Elise Huszar, celebrates 20 years of Geneva leadership, beginning in 1996 as the first full-time Executive Director, and serving as President since 1998.

Geneva Investigator Dr. Travis Warren, in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Gilead Sciences, receives an award to conduct preclinical development of GS-5734 for the treatment of Ebola Virus and other filovirus infections.

Geneva is awarded six TriService Nursing Research Program awards, to be conducted at Andrews Air Force Base, Landstuhl Regional Army Medical Center, Womack Army Medical Center, Wright-Patterson Air Force Base, and U. S. Army Graduate Program in Anesthesia Nursing.

Geneva enters into a Memorandum of Understanding with the Uniformed Services University of the Health Sciences to collaborate on multiple activities for the purpose of conducting medical research and education within the DoD and nationwide.

In honor of Research Month, Geneva employees attend symposiums and events nationwide at military treatment facilities including Dwight D. Eisenhower Army Medical Center, Madigan Army Medical Center, San Antonio Military Medical Center, Walter Reed National Military Medical Center, and Womack Army Medical Center.

Pre-clinical testing for Geneva Investigator Dr. Amy Shurtleff’s newly-developed Hantavirus DNA vaccine commences in Chicago, IL.

Geneva’s Community Giving Program supports joint Base Lewis-McChord’s Veterans Appreciation Day & Health Fair, Nellis Air Force Base’s Clinical Investigation Research Symposium, and the Alan Magill Malaria Symposium at Walter Reed Army Institute of Research.

In honor of Research Month, Geneva hosts the 11th annual National Liver Conference in Dallas, Texas.

Geneva participates in the Ride to Recovery Honor Ride in the National Capital Region, raising funds for Project HERO and also participates in Race for a Soldier at Gig Harbor, WA raising money for the Permission to Start Dreaming (PTSD) Foundation.

Geneva receives a cooperative agreement from Naval Research Laboratory for the initial Phase I funding for the formation of the 4D Bioprinting, Biofabrication, and Biomanufacturing Consortium (4D Bio3).

Geneva partners with the Jonas Center for Nursing and Veterans Healthcare to support Geneva’s first scholarship for a doctoral nursing candidate. The scholarship, matched by Johns Hopkins University, funds Johns Hopkins School of Nursing doctoral candidate Tamar U. Rodney, MSN, RN, PMHNP-BC, whose research goals focus around molecular biomarkers of post-traumatic stress disorder in veterans with traumatic brain injury.

Geneva’s Scientific Advisory Board welcomes two new members, Eleanor F. Bond, PhD, RN, FAAN and Brigadier General (Ret.) John J. Donnelly, PhD.

Founder and Chief Strategy Officer, Jane Taylor, presents at the Tacoma-Pierce County Chamber Spotlight! on Business Awards.

Geneva’s Scientific Advisory Board hosts its annual meeting with visits to the Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center.


Geneva’s President, Elise Huszar, celebrates 20 years of Geneva leadership, beginning in 1996 as the first full-time Executive Director, and serving as President since 1998.

Geneva Investigator Dr. Travis Warren, in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Gilead Sciences, receives an award to conduct preclinical development of GS-5734 for the treatment of Ebola Virus and other filovirus infections.

Geneva is awarded six TriService Nursing Research Program awards, to be conducted at Andrews Air Force Base, Landstuhl Regional Army Medical Center, Womack Army Medical Center, Wright-Patterson Air Force Base, and U. S. Army Graduate Program in Anesthesia Nursing.

Geneva enters into a Memorandum of Understanding with the Uniformed Services University of the Health Sciences to collaborate on multiple activities for the purpose of conducting medical research and education within the DoD and nationwide.

In honor of Research Month, Geneva employees attend symposiums and events nationwide at military treatment facilities including Dwight D. Eisenhower Army Medical Center, Madigan Army Medical Center, San Antonio Military Medical Center, Walter Reed National Military Medical Center, and Womack Army Medical Center.

Pre-clinical testing for Geneva Investigator Dr. Amy Shurtleff’s newly-developed Hantavirus DNA vaccine commences in Chicago, IL.

Geneva’s Community Giving Program supports joint Base Lewis-McChord’s Veterans Appreciation Day & Health Fair, Nellis Air Force Base’s Clinical Investigation Research Symposium, and the Alan Magill Malaria Symposium at Walter Reed Army Institute of Research.

In honor of Research Month, Geneva hosts the 11th annual National Liver Conference in Dallas, Texas.

Geneva participates in the Ride to Recovery Honor Ride in the National Capital Region, raising funds for Project HERO and also participates in Race for a Soldier at Gig Harbor, WA raising money for the Permission to Start Dreaming (PTSD) Foundation.

Geneva receives a cooperative agreement from Naval Research Laboratory for the initial Phase I funding for the formation of the 4D Bioprinting, Biofabrication, and Biomanufacturing Consortium (4D Bio3).

Geneva partners with the Jonas Center for Nursing and Veterans Healthcare to support Geneva’s first scholarship for a doctoral nursing candidate. The scholarship, matched by Johns Hopkins University, funds Johns Hopkins School of Nursing doctoral candidate Tamar U. Rodney, MSN, RN, PMHNP-BC, whose research goals focus around molecular biomarkers of post-traumatic stress disorder in veterans with traumatic brain injury.

Geneva’s Scientific Advisory Board welcomes two new members, Eleanor F. Bond, PhD, RN, FAAN and Brigadier General (Ret.) John J. Donnelly, PhD.

Founder and Chief Strategy Officer, Jane Taylor, presents at the Tacoma-Pierce County Chamber Spotlight! on Business Awards.

Geneva’s Scientific Advisory Board hosts its annual meeting with visits to the Uniformed Services University of the Health Sciences and Walter Reed National Military Medical Center.


Geneva’s President, Elise Huszar, celebrates 20 years of Geneva leadership, beginning in 1996 as the first full-time Executive Director, and serving as President since 1998.

Geneva Investigator Dr. Travis Warren, in collaboration with the U.S. Army Medical Research Institute of Infectious Diseases and Gilead Sciences, receives an award to conduct preclinical development of GS-5734 for the treatment of Ebola Virus and other filovirus infections.
Geneva has specialized capabilities in supporting federally funded and industry sponsored research, including researcher-initiated programs, sponsor-initiated programs, and FDA-regulated, multi-center clinical trials. Geneva’s top 15 research areas, by number of programs, are listed below:

- Blast Injuries
- Bone Health
- Breast Cancer
- Burn Injuries
- Cellular & Tissue Regeneration
- Combat Casualty Care
- Critical Care
- Dermatology
- Emergency Medicine
- Endocrinology
- Evidence Based Practice (EBP)
- Gastroenterology
- General Surgery
- Genomics
- Holistic Medicine
- Hematology
- Hepatology
- Infectious Diseases
- Immunology
- Neurology
- Nursing Research
- Oncology
- Ophthalmology
- Orthopedics
- Otolaryngology (ENT)
- Pain Management
- Pathology
- Pediatrics
- Podiatry
- Pulmonology
- Radiology
- Regenerative Medicine
- Rehabilitative Medicine
- Rheumatology
- Urology
- Women’s Health

Within a Wide Range of Indications
- Blast Injuries
- Bone Health
- Breast Cancer
- Burn Injuries
- Cellular & Tissue Regeneration
- Combat Casualty Care
- Critical Care
- Major Limb Amputation
- Pandemic & Epidemic Diseases
- Physical Therapy
- Post-Traumatic Stress Disorder (PTSD)
- Prostate Cancer
- Sleep Disorders
- Telemedicine
- Tinnitus
- Traumatic Brain Injury (TBI)
- Tropical Diseases
- Vaccine Development
- Wound Healing

The above lists are a sampling of Geneva’s research experience and are not intended to be comprehensive.

$54,605,521
TOTAL 2016 GRANT, CONTRACT, AND AWARD REVENUE

*Graph depicts research portfolio by total number of programs.
WE MUST BE PREPARED TO DO THE SAME JOB AND DELIVER THE BEST POSSIBLE CARE TO OUR WOUNDED WARRIORS ON THE BATTLEFIELD.

COL ELIZABETH A. MANN-SALINAS, PHD, RN, NURSE SCIENTIST
U.S. ARMY INSTITUTE OF SURGICAL RESEARCH

Over the course of Operation Iraqi Freedom, over 4,400 deaths occurred among U.S. military personnel, with over 31,950 people wounded in action. More than 2,340 deaths occurred during Operation Enduring Freedom, with approximately 20,092 people wounded in action.

These numbers are staggering, even with the numerous advances made in combat casualty care over the past decade. Caring for combat casualties on the battlefield can be difficult and complex, including austere working conditions that may involve fire, darkness, extreme temperatures and climates, and rugged terrain. In addition, healthcare providers may lack the knowledge and experience needed to optimally prepare for these complicated trauma situations. An explicit need exists for increased training and experience at the Role 2 (R2) level, which provides advance trauma management, reuscissive surgical techniques, and emergency medical treatment via fixed or mobile facilities. Despite this need, a lack of comprehensive and evidence-based systems to train clinical personnel with the combat medical skills required to perform these life-saving interventions persists.

In 2015, COL Elizabeth A. Mann-Salinas, PhD, RN, Nurse Scientist at the U.S. Army Institute of Surgical Research (USAISR), launched a research project to evaluate the utilization of R2 forward surgical capabilities and trauma care in recent conflicts in order to inform future efforts, guide training, and optimize pre-deployment readiness of combat casualty care providers.

“From our estimation, we have woefully overlooked the importance of evaluating how we are using the R2 capacity to inform how we are going to move forward to train for future contingencies”, said Mann-Salinas. “This is particularly relevant given the emphasis on the expectation of ‘prolonged field care’ in other military theaters of operation”.

COL Mann-Salinas and her research team are completing a comprehensive retrospective review of the Joint Trauma System’s R2 database focusing on patients treated in Afghanistan from 2008 to 2014, at data points including: common interventions performed at R2 facilities, outcomes of interventions provided at R2 compared to R3 (intermediate care at support hospital within combat zone), the impact of terrain and combat support on R2 utilization, optimal time and skill level required to transport patients from R2 following life-saving surgical interventions, and the implications of the above data points on training/education, sustainment, quality assurance, system efficiency/functionality, and research endeavors.

The desired outcome of this research includes an evidence-based standardized trauma readiness platform for all services, providing combat developers with data-driven evidence for improving R2 utilization. COL Mann-Salinas’ research is expected to inform the Defense Health Agency’s, and other policymakers’, efforts to establish policies, procedures, and guidelines for the employment of R2 medical assets in present and future conflicts.

COL Mann-Salinas’ dedication to quality research, collaboration, and mentorship has been the driving force for the R2 team’s professional advancement and the project’s success. As COL Mann-Salinas emphasized, “We all must be prepared to do the same job and deliver the best possible care to our wounded warriors on the battlefield”.

Lung cancer is the second most common type of cancer identified in the U.S., with an estimated 221,100 new diagnoses annually. It is by far the leading cause of cancer-related deaths in the United States, claiming approximately 25% of all cancer deaths. Military personnel are at an increased risk of developing lung cancer due to higher rates of smoking and increased exposure to environmental carcinogens during their time of service.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for an estimated 85-90% of the lung cancer cases. Of these cases, approximately 9,000 have the anaplastic lymphoma kinase (ALK) gene rearrangement. NSCLC patients with the ALK alteration tend to be younger compared with other types of NSCLC, and have never smoked or have a prior light smoking history.

The ALK rearrangement is not a hereditary alteration, but an acquired genetic alteration that develops as the cancer progresses, accelerating the development and growth of tumors. Medications called tyrosine kinase inhibitors (TKIs) have been shown to delay tumor growth or even reverse the size of tumors in patients with ALK rearrangements. While there are several ALK directed TKIs (ALK TKIs) to treat this patient population, in patients with ALK rearrangements. While there are several ALK directed TKIs (ALK TKIs) to treat this patient population, patients who have failed to respond to ALK TKIs, are ALK TKI-naive, and in patients with brain metastases, a common site of disease resistance and recurrence. Additional trials with ensartinib have commenced or are in the planning stages, including trials in patients who are treatment naïve and in combination with an immunotherapy agent or in other disease settings.

Lung cancer is the second most common type of cancer identified in the U.S., with an estimated 221,100 new diagnoses annually. It is by far the leading cause of cancer-related deaths in the United States, claiming approximately 25% of all cancer deaths. Military personnel are at an increased risk of developing lung cancer due to higher rates of smoking and increased exposure to environmental carcinogens during their time of service.

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for an estimated 85-90% of the lung cancer cases. Of these cases, approximately 9,000 have the anaplastic lymphoma kinase (ALK) gene rearrangement. NSCLC patients with the ALK alteration tend to be younger compared with other types of NSCLC, and have never smoked or have a prior light smoking history.

The ALK rearrangement is not a hereditary alteration, but an acquired genetic alteration that develops as the cancer progresses, accelerating the development and growth of tumors. Medications called tyrosine kinase inhibitors (TKIs) have been shown to delay tumor growth or even reverse the size of tumors in patients with ALK rearrangements. While there are several ALK directed TKIs (ALK TKIs) to treat this patient population, patients who have failed to respond to ALK TKIs, are ALK TKI-naive, and in patients with brain metastases, a common site of disease resistance and recurrence. Additional trials with ensartinib have commenced or are in the planning stages, including trials in patients who are treatment naïve and in combination with an immunotherapy agent or in other disease settings.
Hantaviruses are part of the National Institute of Allergy and Infectious Diseases’ (NIAID) Category A Priority Pathogens list, identifying them as organisms/biological agents that pose the highest risk to national security and public health. These viruses are carried by persistently-infected rodents and transmitted by exposure to rodent excreta. At least four Hantaviruses are known to cause thousands of cases of hemorrhagic fever with renal syndrome (HFRS) each year. Of significance, HFRS infections tend to increase during times of severe infrastructure breakdown, such as those that might occur during a biofense emergency because of increased human exposure to rodents. Symptoms of HFRS include intense headaches, back and abdominal pain, fever, chills, nausea, and blurred vision and can progress to acute shock, and kidney failure. Currently, there are no FDA-licensed vaccines for Hantaviruses causing HFRS; rodent control is the primary strategy for preventing infection.

In 2012, Geneva partnered with the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID) and the U.S. Army Medical Materiel Development Activity (USAMMDA), to launch a research program in response to NIAID’s call for a proof-of-concept study to develop a molecular vaccine for HFRS and to test the vaccine through to Phase 1 clinical studies. The research, led by Geneva Principal Investigator Dr. Amy Shurtleff, PhD, in close partnership with Drs. Connie Schmaljohn and Jay Hooper of USAMRIID, proposed to utilize a combination DNA vaccine as a preventative measure against HFRS.

To enhance and accelerate the immune response, the combination DNA vaccine is administered either intramuscularly (IM) or intradermally (ID) using the electroporation-based (EP) TriGrid™ Delivery System (TDS) investigational device. The TDS is a novel, cross-cutting delivery platform manufactured by Ichor Medical Systems, Inc. that utilizes the application of electrical pulses at the site of DNA vaccine administration. The pulses allow the vaccine to enter the cells more effectively, leading to an enhanced immune response. Additionally, the combination vaccine technology makes it an ideal candidate for protection against four pathogenic hantaviruses endemic to different parts of the world.
A Growing Organization

Geneva employees join forces with some of the world’s leading researchers, whose teams are committed to the advancement of military medicine to improve the lives of U.S. service members & veterans, their families, and the global community.

Geneva recruits only the best and brightest in their field - that’s why we have such an incredible team.

JENNIFER GRIFFITH, SENIOR HUMAN RESOURCES DIRECTOR
THE GENEVA FOUNDATION

Wave the Flag

Geneva recognizes excellence in employees who go above and beyond the normal scope of their work, demonstrate Geneva’s values, and strengthen Geneva’s mission of promoting and supporting the advancement of military medicine.

Q1 RECIPIENT
DR. VICTORIA TEPE
Research Portfolio Manager
Department of Defense Hearing Center of Excellence

Q2 RECIPIENT
STEPHANIE DELEON
Clinical Research Coordinator
Major Extremity Trauma Research Consortium Team, San Antonio Military Medical Center

Q3 RECIPIENT
THOMAS HIEL
Research Engineer
Walter Reed National Military Medical Center

Q4 RECIPIENT
SESHAMALINI SRINIVASAN
Research Associate III
U.S. Army Center for Environmental Health Research

175 EMPLOYEES HIRED IN 2016, WITH OVER 525 EMPLOYEES WORLDWIDE

1993 2 EMPLOYEES
2003 56 EMPLOYEES
2008 89 EMPLOYEES
2010 147 EMPLOYEES
2013 351 EMPLOYEES
2016 526 EMPLOYEES

and award revenue $54,605,521

216 th total 2016 grant, contract, 175 employees hired in 2016, with over 525 employees worldwide

260 principal investigators worldwide

160 sponsors and collaborating partners

530 research programs

$309,021,149 in submissions for the year over worldwide

Geneva recognizes excellence in employees who go above and beyond the normal scope of their work, demonstrate Geneva’s values, and strengthen Geneva’s mission of promoting and supporting the advancement of military medicine.
Geneva remains a proud collaborator with a variety of federal government agencies, corporations, foundations, universities, and other partners. Geneva is deeply grateful to those who support and contribute to the success of Geneva’s numerous research programs within the military medical community. Thank you to Geneva’s 2016 sponsors and collaborating partners:

**Sponsors & Collaborating Partners**

- AbbVie, Inc.
- Acutus Medical, Inc.
- Air Force Office of Scientific Research
- Air Force Research Lab
- ALP Life Sciences
- American University
- Andromeda, Inc.
- Applied Research Associates
- Argus Therapeutics, Inc.
- Army Research Office
- Arrowhead Neuroscience Foundation, Inc.
- Arexix, Inc.
- AsanaZeneus
- Aura Medical
- AxoGen, Inc.
- BADER Consortium/University of Delaware
- Baruch S. Blumberg Institute
- BioCryst Pharmaceuticals, Inc.
- Biofactura
- Biostuctures, LLC
- Boehringer Ingelheim
- Boston Biomedical
- Boston University
- Bristol-Myers Squibb
- Buffalo Institute for Medical Research
- Castle Biosciences
- Celmic, LLC
- CEL-SCI
- Cempra Pharmaceuticals
- Center for Disease Control
- CFD Research Corporation
- Children’s Oncology Group (COG)
- Chiron Corporation
- Cirrus Therapeutics
- Columbia University
- Combat Casualty Care Research Program
- Conatus Pharmaceuticals
- Congestionally Directed Medical Research Programs
- Cryoan
- Defense Threat Reduction Agency
- Detroit Receiving Hospital & Sinai-Grace Hospital
- Dexcom, Inc.
- Duke Clinical Research Institute
- Emory University Grady Memorial Hospital
- EpicenterX
- Exelis Biocense Ltd.
- Flexion Therapeutics
- Fraunhofer USA
- Goelzin Therapeutics, Inc.
- Galmed Pharmaceuticals Ltd.
- Genfit
- George Mason University
- Georgia Regents University
- Gilead Sciences, Inc.
- Griffiths International, S.A.
- Ishar Medical Systems, Inc.
- Immunities
- Integrated Biotherapeutics, Inc.
- Intercept Pharmaceuticals
- Johns Hopkins University
- Kessler Foundation
- Leidos, Inc.
- Leuvehce Respiratory Research Institute
- Mahidol University
- Maine Ken Technologies
- Mayo Clinic
- MDOD Research & Informatics
- Medical College of Wisconsin
- Medpace, Inc.
- Merck & Co., Inc.
- Microbiovit, Inc.
- Military Operational Medicine Research Program
- Military Suicide Research Consortium
- Novant Contracting Division
- National Institute on Deafness and Other Communication Disorders
- National Institutes of Health
- National Strategic Research Institute
- National Institute of Deafness and Other Communication Disorders
- Natick Contracting Division
- National Institute on Deafness and Other Communication Disorders
- Medical College of Wisconsin
- Mayo Clinic
- Medpace, Inc.
- Merck & Co., Inc.
- Microbiovit, Inc.
- Military Operational Medicine Research Program
- Military Suicide Research Consortium
- Novant Contracting Division
- National Institute on Deafness and Other Communication Disorders
- National Institutes of Health
- National Strategic Research Institute
- Naval Medical Logistics Command
- Naval Research Laboratory
- Neuren Pharmaceuticals
- New York University
- Neuro Kinetics, Inc.
- New York University School of Medicine
- NewLink Genetics Corporation
- Novartis
- Nuvist Pacs/AS
- Nuviva, Inc.
- One Federal Solution, Inc.*
- Oregon Health & Science University
- OtisScience Labs, LLC
- Palo Alto Veterans Institute for Research
- PARXEL International Corporation
- Pherix Therapeutics
- PneumRx, Inc.
- Portland State University
- PRAM Health Sciences
- Pryme Medical Devices, Inc.
- Queen’s Medical Center
- Regeneron
- Regenesis Biomedical, Inc.
- Rhone Island Hospital
- Roche
- RTI Surgical, Inc.
- Rutgers, The State University of New Jersey
- Shire
- Southern Illinois University
- Spectrum Pharmaceuticals
- SPR Therapeutics
- St. Luke’s Health Network
- Taiho Pharmaceuticals Co., Ltd.
- Temple University
- Texas A&M University
- Texas Tech University Health Sciences Center
- TG Therapeutics, Inc.
- The Mind Research Network
- The Research Foundation for The State University of New York
- Stony Brook University
- Tobra Therapeutics, Inc.
- TrService Nursing Research Program
- U.S. Army Medical Material Development Activity
- U.S. Army Medical Research & Materiel Command
- U.S. Army Medical Research Institute of Chemical Defense
- U.S. Army Medical Research Institute of Neurological Surgery
- University of Arkansas
- University of California, San Diego
- University of Florida
- University of Illinois
- University of Miami, Miller School of Medicine
- University of Pennsylvania
- University of Pittsburgh
- University of Southern Alabama
- University of Texas Health Science Center at Houston
- University of Texas Southwestern Medical Center at Dallas
- University of Utah
- United States Army Medical Research Acquisition Activity
- VentureRx Pharmaceuticals
- Virginia Commonwealth University
- Wayne State University
- West Virginia University Research Corporation
- Wright State University
- Xobitech
- Zcore Business Solutions, Inc.*

*Indicates small business

160
SPONSORS AND COLLABORATING PARTNERS
WORLDWIDE

79
INDUSTRY

18
NON-PROFIT & HOSPITAL SYSTEMS

40
ACADEMIA & RESEARCH INSTITUTES

21
FEDERAL
Geneva has continued to deliver strong financial performance in 2016, with total grant, contract, and award revenue up approximately 11% over the previous year.

Financial Snapshot

Geneva has continued to deliver strong financial performance in 2016, with total grant, contract, and award revenue up approximately 11% over the previous year.

Research Programs by Revenue*

In 2016, Geneva managed over $54.6 million of research in a wide range of research areas and indications. Geneva’s top 15 research areas, by revenue, are listed below.

5 Largest Awards

1. GS-5734 FOR THE TREATMENT OF EBOLA VIRUS
   Dr. Travis Warren, USAMRIID

2. NATICK BLANKET PURCHASE AGREEMENT
   Awarded by Natick Contracting Division as Contract No. W911QY-16-A-0014
   MAJ Daniel Rhon, MAJ Christopher Allen, BAMC • MAJ Mark Lester, MAJ Angela Diebal, COL Scott Shaffer, AMEDDC&S • MAJ John Mason, KACH
   Dr. Vance Sohn, MAMC • Lt (P) Robert Whitehurst, WAMC • Dr. Christopher Maani, SAMMC

3. ONE ACQUISITION SOLUTION FOR INTEGRATED SERVICES (OASIS) PROGRAM MANAGEMENT AND SCIENTIFIC SUPPORT SERVICES
   Funded by Naval Medical Logistics Command on the OASIS schedule through an agreement with Leidos, Inc. under Award No. N62645-16-F-0028, N62645-16-F-0062, and N62645-16-F-0060
   NMCP • NMCSD

4. A NOVEL VECTOR CONTROL MEASURE TO COMBAT THE SPREAD OF ARTEMISININ RESISTANCE IN THE GREATER MEKONG SUBREGION
   Funded by United States Army Medical Research Acquisition Activity through an agreement with Mahidol University under Award No. W81XWH-16-0021
   Dr. Kevin Kobylinski, AFRIMS

5. ULTRASENSITIVE, RAPID, EARLY DETECTION OF EBOLA ANTIGEN (SGP) USING M-PLATE, A NEW NANOSTRUCTURED PLATE WITH ULTRA-HIGH AMPLIFICATION
   Funded by Defense Threat Reduction Agency under Award No. HDTRA1-16-C-0025
   Dr. Amy Shurtleff, USAMRIID
The Geneva Foundation is a 501(c) 3 non-profit organization that supports innovative medical research and excellence in education within the U.S. military. We build enduring partnerships dedicated to the health and well-being of service members, their families, and the global community.

The Geneva Foundation | 917 Pacific Ave., Suite 600 | Tacoma, Washington 98402
GenevaUSA.org

© The Geneva Foundation, 2017